Investor Presentaiton
4
Investor presentation
Full year 2022
Novo NordiskⓇ
Strategic Aspirations 2025 | Highlights full year 2022
Purpose and
sustainability
(ESG)
Progress towards zero environmental impact
Carbon emissions decreased by 29% vs 20191
Adding value to society
Medical treatment provided to 36.3 million people living
with diabetes
Reaching more than 41,000 children in Changing
Diabetes in Children programme
Being recognised as a sustainable employer
Share of women in VP+ positions increased to 39% from
36% in 2021
ピ
Diabetes value market share increased by 1.8%-points
to 31.9%3
Obesity care sales of DKK 16.9 billion (+84% at CER)
Rare disease sales of DKK 20.5 billion (+1% at CER)
Commercial
execution
therapeutic focus
Innovation and
Financials
•
•
Light blue indicates developments in Q4 2022
Further raise innovation bar for Diabetes treatment
Completion of phase 3a trials with QW insulin icodec
Completion of phase 2 trial with CagriSema in T2D
Develop superior treatment solutions for obesity
Phase 3 initiated with CagriSema in people with obesity
Strengthen and progress Rare disease pipeline
•
•
•
Concizumab phase 3 trial completed²
Phase 3a trial initiated with Mim8 in Haemophilia A
Establish presence in Other serious chronic diseases
Two phase 1 trials initiated in NASH utilising siRNA
Sales growth of 16% (CER) and Operating profit growth
of 15% (CER)
•
.
Sales in International Operations grew by 13% (CER)
• Sales in the US grew by 19% (CER) with 73% of sales
coming from products launched since 2015
Gross margin positively impacted by continued
productivity gains in Product Supply
Free cash flow of DKK 57.4 billion and DKK 49.4 billion
returned to shareholders in 2022
1 Partial scope 3 limited to CO2 emissions from business flights and product distribution; 2in people with Haemophilia A and B with and without inhibitors; 3MAT (Moving annual total) value market share
EMA: European Medicines Agency; VP: Vice president; QD: Once-daily; QW: Once-weekly; CER: Constant exchange rates; T2D: Type 2 diabetes; HA: Haemophilia A; HB: Haemophilia B; SCD: Sickle Cell Disease
Note: The strategic aspirations are not a projection of Novo Nordisk's financial outlook or expected growthView entire presentation